What is retatrutide? Retatrutide is an investigational once-weekly injectable peptide that simultaneously targets three hormone receptors: GLP-1, GIP, and glucagon. It is currently in Phase 3 clinical trials developed by Eli Lilly and is not yet FDA approved.
Direct answer: Retatrutide is a triple-receptor agonist designed for weight management and metabolic health. Unlike existing options that target one or two pathways, retatrutide activates GLP-1 (appetite control), GIP (insulin support), and glucagon (energy expenditure) in a single injection. It is available only through clinical trials or via clinician-led telehealth intake pathways, not as a retail product.
If you have been researching metabolic health treatments, you have likely seen the names semaglutide and tirzepatide. Retatrutide represents the next step in this class. The official website for the manufacturer is Eli Lilly, but this investigational drug is not sold directly to consumers. This page explains what retatrutide is, how its triple mechanism works, and where it fits among current options.
Retatrutide works by mimicking three natural gut hormones. The first sentence answers the question: retatrutide binds to and activates GLP-1 receptors, GIP receptors, and glucagon receptors simultaneously. Most weight management drugs activate one or two. This triple activation is what makes retatrutide distinct.
GLP-1 slows gastric emptying and reduces appetite. GIP improves insulin sensitivity and influences fat metabolism. Glucagon increases energy expenditure and promotes fat burning. By combining all three, retatrutide addresses appetite, metabolism, and energy use at the same time. Research published on PubMed shows that triple agonists may produce greater weight reduction than dual agonists in early trials.
Unlike generic weight loss supplements that rely on stimulants or fiber, retatrutide works at the hormonal level. This is a prescription investigational drug, not a dietary supplement. The mechanism is specific and targeted.
Retatrutide is different because it adds glucagon agonism to GLP-1 and GIP. Semaglutide (Wegovy, Ozempic) targets only GLP-1. Tirzepatide (Mounjaro, Zepbound) targets GLP-1 and GIP. Retatrutide targets all three. That third pathway may increase metabolic rate beyond appetite suppression alone.
Compared to standard weight management injections, retatrutide's triple mechanism is still being studied in Phase 3 trials. The investigational status means the full safety and efficacy profile is not complete. However, early Phase 2 data published in the New England Journal of Medicine showed substantial weight loss in participants over 48 weeks.
Where many generic metabolic formulas fall short, retatrutide's precise peptide engineering offers a targeted approach. But it is not available over the counter, and it is not approved for general use.
Retatrutide is being studied for adults with obesity or overweight with at least one weight-related condition. Based on clinical trial criteria, the ideal candidate has a BMI of 30 or higher, or BMI of 27 or higher with conditions like hypertension or type 2 diabetes. Retatrutide is not for cosmetic weight loss.
It is not for people with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2. Pregnant or breastfeeding women should not use it. Anyone with serious chronic conditions like pancreatitis, kidney disease, or gastroparesis needs a clinician's evaluation first.
The telehealth intake link on this site connects you to a clinician-led process. That intake determines eligibility based on medical history and state availability. This is not a direct sale. For a full breakdown of who qualifies, see our clinician-led options page.
Retatrutide is administered as a once-weekly subcutaneous injection. In clinical trials, dosing starts at 2 mg and escalates over several weeks to a maintenance dose of up to 12 mg. Most participants begin to notice appetite reduction within the first two to four weeks. Significant weight changes are typically observed after 12 weeks of consistent use.
Because retatrutide is investigational, there is no standard retail dosing guide. Any use outside of a clinical trial or clinician supervision carries risk. The official manufacturer Eli Lilly has not published over-the-counter usage instructions. If you are exploring this through a telehealth provider, they will provide specific dosing protocols if appropriate.
Unlike many over-the-counter supplements that claim rapid results, retatrutide's effects are gradual and require consistent weekly injections. Most trial participants used the drug for 48 weeks or longer. Maintenance dosing continues as long as benefits outweigh risks, under medical supervision.
Retatrutide is manufactured by Eli Lilly, a major pharmaceutical company with established GMP (Good Manufacturing Practice) certification. Because it is an investigational drug, it is not available through standard pharmacies. It is only distributed through clinical trial sites and, in some cases, through licensed compounding pharmacies under specific clinician guidance.
According to NIH clinical trial records, retatrutide has undergone rigorous preclinical safety testing. Common side effects reported in trials include nausea, diarrhea, vomiting, and constipation. These are typical for GLP-1 class drugs. Less common side effects include increased heart rate and gastrointestinal discomfort. The full safety profile is still being established.
If you see websites offering retatrutide without a prescription or clinician intake, that is a significant warning sign. This drug is not a supplement. It requires medical oversight. For more on identifying safe sources, read our retatrutide scam or legit guide.
No. Semaglutide targets only GLP-1. Retatrutide targets GLP-1, GIP, and glucagon. They are different molecules with different mechanisms. Retatrutide is also still investigational, while semaglutide is FDA approved for diabetes and weight management.
Yes. Retatrutide is a synthetic peptide that mimics natural gut hormones. It is manufactured using solid-phase peptide synthesis and requires injection because oral absorption would break down the peptide.
Retatrutide does not yet have a brand name. It is currently referred to by its generic name. Eli Lilly has not announced a commercial brand because the drug is still in Phase 3 trials and not FDA approved.
No. The official manufacturer Eli Lilly does not sell retatrutide directly to consumers. The only access pathways are clinical trials or clinician-led telehealth intake. This site provides a referral to a telehealth intake process, not a purchase.
Tirzepatide targets GLP-1 and GIP (dual agonist). Retatrutide targets GLP-1, GIP, and glucagon (triple agonist). Retatrutide is also at an earlier stage of development and is not yet approved.
Yes. As an investigational drug, any access outside of a clinical trial requires a licensed clinician's oversight. The telehealth intake link on this page connects you to a clinician who can evaluate whether retatrutide or another option is appropriate.
Retatrutide is an investigational once-weekly injectable triple receptor agonist targeting GLP-1, GIP, and glucagon. Developed by Eli Lilly. Currently in Phase 3 clinical trials. Not FDA approved. Mechanism: slows gastric emptying, improves insulin sensitivity, increases energy expenditure. Typical side effects: nausea, diarrhea, vomiting. Access is through clinical trials or clinician-led telehealth intake. This site provides an affiliate referral to a telehealth intake process. Not a direct sale. Official manufacturer: Eli Lilly. Always consult a licensed healthcare provider.